PFEPfizer

Health care · Pharmaceuticals · NYSE

Pfizer Inc. is a research-based, global biopharmaceutical company. 10-K, Item 1

Employees: 75,000
Headquarters: New York, NY
CEO: Albert Bourla
Next results: around Feb 2, 2027

The numbers PFE said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.

Of 2 range targets with a reported result: 0 came in above the last range given, 2 within it, 0 below it.

Target	What the company said	Reported	Result
Diluted EPS (company-defined) Fiscal 2026	Given $2.80 to $3.00 release 2026-02-03 Kept $2.80 to $3.00 release 2026-05-05 Kept $2.80 to $3.00 release 2026-08-04 Raised $2.95 to $3.05 release 2026-11-03	–	No standard number
The company's words Today, we are reaffirming our full-year 2026 financial guidance.” … Reaffirms All Components of Full-Year 2026 Financial Guidance (1) , including Revenues in a Range of $59.5 to $62.5 Billion and Adjusted (3) Diluted EPS in a Range of $2.80 to $3.00. release 2026-02-03 Reaffirms All Components of Full-Year 2026 Financial Guidance (2) , including Revenues in a Range of $59.5 to $62.5 Billion and Adjusted (4) Diluted EPS in a Range of $2.80 to $3.00. release 2026-05-05 Reaffirms Full-Year 2026 Adjusted (3) Diluted EPS Guidance in a Range of $2.80 to $3.00, which Absorbs an Impact of Approximately $0.10 Related to the Innovent Biologics, Inc. Transaction. release 2026-08-04 Raises and Narrows Full-Year 2026 Adjusted (3) Diluted EPS Guidance to a Range of $2.95 to $3.05 release 2026-11-03
Revenue Fiscal 2026	Given $59.50B to $62.50B release 2026-02-03 Kept $59.50B to $62.50B release 2026-05-05 Raised $60.50B to $62.50B release 2026-08-04 Raised $62.00B to $64.00B release 2026-11-03	–	Not reported yet
The company's words Reaffirms full-year 2026 Revenue guidance in a range of $59.5 to $62.5 billion and Adjusted (3) diluted EPS guidance (1) in a range of $2.80 to $3.00. release 2026-02-03 Reaffirms all components of full-year 2026 Financial Guidance (2) , including Revenues in a range of $59.5 to $62.5 billion and Adjusted (4) Diluted EPS in a Range of $2.80 to $3.00. … Revenues $59.5 to $62.5 billion release 2026-05-05 Raises Full-Year 2026 Revenue Guidance (2) by $500 Million at the Midpoint to a Range of $60.5 to $62.5 Billion release 2026-08-04 Raises Full-Year 2026 Revenue Guidance (2) by $1.5 billion at the Midpoint to a Range of $62.0 to $64.0 billion release 2026-11-03
Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31)	Given $2.80 to $3.00 release 2025-02-04 Kept $2.80 to $3.00 release 2025-04-29 Raised $3.00 to $3.15 release 2025-11-04	–	No standard number
The company's words Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance … Reaffirms All Components of Full-Year 2025 Financial Guidance (5) , including Revenues in a Range of $61.0 to $64.0 Billion and Adjusted (3) Diluted EPS in a Range of $2.80 to $3.00 release 2025-02-04 2025 FINANCIAL GUIDANCE … Reaffirms All Components of Full-Year 2025 Financial Guidance (1) , including Revenues in a Range of $61.0 to $64.0 Billion and Adjusted (3) Diluted EPS in a Range of $2.80 to $3.00. release 2025-04-29 Raises and narrows Full-Year 2025 Adjusted (2) Diluted EPS Guidance (1) to a Range of $3.00 to $3.15 release 2025-11-04
Revenue Fiscal 2025 (ended 2025-12-31)	Given $61.00B to $64.00B release 2025-02-04 Kept $61.00B to $64.00B release 2025-04-29 Kept $61.00B to $64.00B release 2025-08-05 Kept $61.00B to $64.00B release 2025-11-04	$62.58B 10-K filed 2026-02-26	Within the range
The company's words Pfizer’s 2025 financial guidance (5) is presented below. … Revenues $61.0 to $64.0 billion release 2025-02-04 Pfizer’s 2025 financial guidance (1) is presented below. … Revenues $61.0 to $64.0 billion release 2025-04-29 Reaffirms Full-Year 2025 Revenue Guidance (1) in a Range of $61.0 to $64.0 Billion release 2025-08-05 Reaffirms Full-Year 2025 Revenue Guidance (1) in a Range of $61.0 to $64.0 Billion release 2025-11-04
Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31)	Given $2.05 to $2.25 release 2024-01-30	–	No standard number
The company's words 2024 Adjusted (3) diluted EPS is anticipated to be in a range of $2.05 to $2.25, which primarily reflects: release 2024-01-30
Revenue Fiscal 2024 (ended 2024-12-31)	Given $58.50B to $61.50B release 2024-01-30 Kept $58.50B to $61.50B release 2024-05-01 Raised $59.50B to $62.50B release 2024-07-30 Raised $61.00B to $64.00B release 2024-10-29	$63.63B 10-K filed 2025-02-27	Within the range
The company's words Reaffirms Full-Year 2024 Guidance (5) Provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted (3) Diluted EPS of $2.05 to $2.25 release 2024-01-30 Reaffirms Full-Year 2024 Revenue Guidance (6) of $58.5 to $61.5 Billion and Raises Adjusted (3) Diluted EPS Guidance to $2.15 to $2.35 release 2024-05-01 Raises Full-Year 2024 Revenue Guidance (1) to a Range of $59.5 to $62.5 Billion and Raises Adjusted (2) Diluted EPS Guidance to a Range of $2.45 to $2.65 release 2024-07-30 Raises Full-Year 2024 Revenue Guidance (1) to a Range of $61.0 to $64.0 Billion and Raises Adjusted (2) Diluted EPS Guidance to a Range of $2.75 to $2.95 release 2024-10-29

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2023-12-14), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Work on PFE in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/PFE/export.csv") into a cell.